Skip to main content

American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing.

Publication ,  Journal Article
Middeldorp, S; Nieuwlaat, R; Baumann Kreuziger, L; Coppens, M; Houghton, D; James, AH; Lang, E; Moll, S; Myers, T; Bhatt, M; Colunga-Lozano, LE ...
Published in: Blood Adv
November 28, 2023

Hereditary and acquired thrombophilia are risk factors for venous thromboembolism (VTE). Whether testing helps guide management decisions is controversial. These evidence-based guidelines from the American Society of Hematology (ASH) intend to support decision making about thrombophilia testing. ASH formed a multidisciplinary guideline panel covering clinical and methodological expertise and minimizing bias from conflicts of interest. The McMaster University GRADE Centre provided logistical support, performed systematic reviews, and created evidence profiles and evidence-to-decision tables. The Grading of Recommendations Assessment, Development, and Evaluation approach (GRADE) was used. Recommendations were subject to public comment. The panel agreed on 23 recommendations regarding thrombophilia testing and associated management. Nearly all recommendations are based on very low certainty in the evidence due to modeling assumptions. The panel issued a strong recommendation against testing the general population before starting combined oral contraceptives (COCs) and conditional recommendations for thrombophilia testing in the following scenarios: (a) patients with VTE associated with nonsurgical major transient or hormonal risk factors; (b) patients with cerebral or splanchnic venous thrombosis, in settings where anticoagulation would otherwise be discontinued; (c) individuals with a family history of antithrombin, protein C, or protein S deficiency when considering thromboprophylaxis for minor provoking risk factors and for guidance to avoid COCs/hormone replacement therapy; (d) pregnant women with a family history of high-risk thrombophilia types; and (e) patients with cancer at low or intermediate risk of thrombosis and with a family history of VTE. For all other questions, the panel provided conditional recommendations against testing for thrombophilia.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood Adv

DOI

EISSN

2473-9537

Publication Date

November 28, 2023

Volume

7

Issue

22

Start / End Page

7101 / 7138

Location

United States

Related Subject Headings

  • Venous Thromboembolism
  • United States
  • Thrombophilia
  • Pregnancy
  • Humans
  • Hematology
  • Female
  • Antithrombins
  • Anticoagulants
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Middeldorp, S., Nieuwlaat, R., Baumann Kreuziger, L., Coppens, M., Houghton, D., James, A. H., … Iorio, A. (2023). American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv, 7(22), 7101–7138. https://doi.org/10.1182/bloodadvances.2023010177
Middeldorp, Saskia, Robby Nieuwlaat, Lisa Baumann Kreuziger, Michiel Coppens, Damon Houghton, Andra H. James, Eddy Lang, et al. “American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing.Blood Adv 7, no. 22 (November 28, 2023): 7101–38. https://doi.org/10.1182/bloodadvances.2023010177.
Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, Coppens M, Houghton D, James AH, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023 Nov 28;7(22):7101–38.
Middeldorp, Saskia, et al. “American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing.Blood Adv, vol. 7, no. 22, Nov. 2023, pp. 7101–38. Pubmed, doi:10.1182/bloodadvances.2023010177.
Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, Coppens M, Houghton D, James AH, Lang E, Moll S, Myers T, Bhatt M, Chai-Adisaksopha C, Colunga-Lozano LE, Karam SG, Zhang Y, Wiercioch W, Schünemann HJ, Iorio A. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023 Nov 28;7(22):7101–7138.

Published In

Blood Adv

DOI

EISSN

2473-9537

Publication Date

November 28, 2023

Volume

7

Issue

22

Start / End Page

7101 / 7138

Location

United States

Related Subject Headings

  • Venous Thromboembolism
  • United States
  • Thrombophilia
  • Pregnancy
  • Humans
  • Hematology
  • Female
  • Antithrombins
  • Anticoagulants
  • 3201 Cardiovascular medicine and haematology